<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35811082</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics of the Omicron variant - results from a Nationwide Symptoms Survey in the Faroe Islands.</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>643</EndPage><MedlinePgn>636-643</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2022.07.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(22)00405-2</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Omicron appears to lead to a milder illness for patients compared with previous COVID-19 variants. However, not all infected with Omicron would describe their illness as mild. In this study, we investigate the experienced severity and symptoms of the Omicron variant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a nationwide cross-sectional study, including 5036 individuals of all ages, consisting of reverse transcription-polymerase chain reaction confirmed SARS-CoV-2 cases from 1 January to 31 January 2022 (n&#xa0;=&#xa0;4506) and a control group without SARS-COV-2 infection in December 2021 or January 2022 (n&#xa0;=&#xa0;530). Omicron was dominant during this period. Cases were asked about their acute symptoms and answered a web-based questionnaire 10-30 days after their positive test while controls were asked about symptoms during the past week.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among cases, 97% reported at least one symptom during the acute phase compared with 79% of controls. Just over half the cases assessed their illness as asymptomatic or mild, whereas 46% assessed their illness as moderate or severe. Children reported fewer symptoms and less severe illnesses than adults (P &lt;0.001). The largest risk differences (RDs) between adult cases and controls due to symptoms were observed for fever (RD&#xa0;=&#xa0;60.6%, confidence interval [CI] 57.4-63.6), fatigue (RD&#xa0;=&#xa0;49.6%, CI 44.1-54.7), and chills (RD&#xa0;=&#xa0;48.8%, CI 43.8-53.2).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Most of those infected with Omicron experience symptoms, and the Omicron variant appears to lead to less severe disease. However, this does not mean that all the infected experience an Omicron infection as mild. The unprecedented rate of Omicron infections worldwide leads to urgent questions about the rate of long COVID after Omicron infections.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Maria Skaalum</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>The Faroese Hospital System, the Department of Occupational Medicine and Public Health, T&#xf3;rshavn, Faroe Islands; University of the Faroe Islands, Center of Health Science, T&#xf3;rshavn, Faroe Islands. Electronic address: maria@health.fo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xcd; Kongsstovu</LastName><ForeName>Sunnv&#xf8;r</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Faroese Hospital System, the Department of Occupational Medicine and Public Health, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eliasen</LastName><ForeName>Eina H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>The Faroese Hospital System, the Department of Occupational Medicine and Public Health, T&#xf3;rshavn, Faroe Islands; University of the Faroe Islands, Center of Health Science, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>S&#xf3;lrun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Chief Medical Office, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>J&#xf3;hanna Lj&#xf3;s&#xe1;</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Chief Medical Office, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vest</LastName><ForeName>Nicolina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Faroese Food and Veterinary Authority, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dahl</LastName><ForeName>Maria Marjunard&#xf3;ttir</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faroese Food and Veterinary Authority, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christiansen</LastName><ForeName>Debes Hammershaimb</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Faroese Food and Veterinary Authority, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Lars Fodgaard</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Chief Medical Office, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristiansen</LastName><ForeName>Marnar Fr&#xed;&#xf0;heim</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>The Faroese Hospital System, the Department of Occupational Medicine and Public Health, T&#xf3;rshavn, Faroe Islands; The National Hospital of the Faroe Islands, Medical Department, T&#xf3;rshavn, Faroe Islands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Clinical characteristics, Faroe Islands</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Survey</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>10</Day><Hour>19</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35811082</ArticleId><ArticleId IdType="pmc">PMC9303132</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2022.07.005</ArticleId><ArticleId IdType="pii">S1201-9712(22)00405-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al. Decreased severity of disease during the first global Omicron variant COVID-19 outbreak in a large hospital in Tshwane, South Africa. Int J Infect Dis. 2022;116:38&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8713416</ArticleId><ArticleId IdType="pubmed">34971823</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA. 2022;327:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of previous infection and vaccination on symptomatic Omicron infections. N Engl J Med. 2022;387:21&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet Infectious Diseases. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnood SA, Shafran R, Bennett SD, Zhang AXD, O'Mahoney LL, Stephenson TJ, et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis of controlled and uncontrolled studies. J Infect. 2022;84:158&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604800</ArticleId><ArticleId IdType="pubmed">34813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, Mohn KG, Brokstad KA, Zhou F, Linchausen DW, Hansen BA, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021;27:1607&#x2013;1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyes R. Forester: an R package for creating publication-ready forest plot, https://github.com/rdboyes/forester, 2021 (accessed on 23 March 2022)</Citation></Reference><Reference><Citation>Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin DR, Abu-Raddad LJ, Andrews N, Davies MA, Higdon MM, Orenstein WA, et al. Assessing vaccine effectiveness against severe COVID-19 disease caused by Omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022;40:3516&#x2013;3527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9058052</ArticleId><ArticleId IdType="pubmed">35595662</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O&#x2019;Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium REDCap. The REDCap consortium: Building an international community of software partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen CH, Schelde AB, Moustsen-Helm EHD, Krause TG, M&#xf8;lbak K, et al. Vaccine effectiveness against infection and COVID-19-associated hospitalisation with the Omicron (B.1.1.529) variant after vaccination with the BNT162b2 or mRNA-1273 vaccine: a nationwide Danish cohort study. ResearchSquare. March 2022 doi: 10.21203/rs.3.rs-1486018/v1. accessed on 10 April 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1486018/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmsdal G, Hansen OK, M&#xf8;ller LF, Christiansen DH, Petersen MS, Kristiansen MF. Omicron outbreak at a private gathering in the Faroe Islands, infecting 21 of 33 triple-vaccinated healthcare workers. Clin Infect Dis. 2022:ciac089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9383377</ArticleId><ArticleId IdType="pubmed">35134167</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobucci G. COVID-19: runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show. BMJ. 2021;375:n3103.</Citation><ArticleIdList><ArticleId IdType="pubmed">34916215</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt D. Omicron is milder. https://www.nytimes.com/2022/01/05/briefing/omicron-risk-milder-pandemic.html, 2022 (accessed 17 March 2022).</Citation></Reference><Reference><Citation>Li A, Maier A, Carter M, Guan TH. Omicron and S-gene target failure cases in the highest COVID-19 case rate region in Canada-December 2021. J Med Virol. 2022;94:1784&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015418</ArticleId><ArticleId IdType="pubmed">34964500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Nocini R, Henry BM. Analysis of online search trends suggests that SARS-CoV-2 Omicron (B.1.1.529) variant causes different symptoms. J Infect. 2022;84:e76&#x2013;e77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8851877</ArticleId><ArticleId IdType="pubmed">35183609</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano AD, Brunkard JM, Boehmer TK, Peterson E, Adjei S, Binder AM, et al. Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020&#x2013;January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351529</ArticleId><ArticleId IdType="pubmed">35085225</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisa A, Spaccaferri G, Fournier L, Schaeffer J, Deniau J, Rolland P, et al. First cases of Omicron in France are exhibiting mild symptoms, November 2021&#x2013;January 2022. Infect Dis Now. 2022;52:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9194534</ArticleId><ArticleId IdType="pubmed">35167979</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuade JGM. riskCommunicator: G-computation to estimate interpretable epidemiological effects. R package version 1.1.1, https://cran.r-project.org/web/packages/riskCommunicator/riskCommunicator.pdf, 2022. (accessed on 23 March 2022)</Citation></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of Omicron and Delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance &#x2013; One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8830624</ArticleId><ArticleId IdType="pubmed">35143466</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, &#xc1; Steig B, Gaini S, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73:e4058&#x2013;e4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Str&#xf8;m M, Christiansen DH, Fjallsbak JP, Eliasen EH, Johansen M, et al. Seroprevalence of SARS-CoV-2-Specific antibodies, Faroe Islands. Emerg Infect Dis. 2020;26:2761&#x2013;2763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7588539</ArticleId><ArticleId IdType="pubmed">32726200</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Str&#xf8;m M, Fjallsbak JP, Hansen JL, Larsen S, Eliasen EH, et al. Low seroprevalence among undetected COVID-19 cases, Faroe Islands, November 2020. Emerg Infect Dis. 2022;28:242&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8714219</ArticleId><ArticleId IdType="pubmed">34757895</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376:eabn4947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995029</ArticleId><ArticleId IdType="pubmed">35289632</ArticleId></ArticleIdList></Reference><Reference><Citation>Raju MK, Thangaraj JWV, Selvavinayagam TS, Somasundaram A, Parthipan K, Sivadoss R, et al. Clinical profile of patients infected with suspected SARS-CoV-2 Omicron variant of concern, Tamil Nadu, India, December 2021&#x2013;January 2022. Indian J Med Res. 2022;155:165&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552397</ArticleId><ArticleId IdType="pubmed">35417991</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8678541</ArticleId><ArticleId IdType="pubmed">34916273</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;ssler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N Engl J Med. 2022;386:698&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8781314</ArticleId><ArticleId IdType="pubmed">35021005</ArticleId></ArticleIdList></Reference><Reference><Citation>The Government of the Faroe Islands  . T&#xf3;rshavn; Faroe Islands: 2022. Corona statistics in the Faroe Islands.https://korona.fo/hagtol-koppseting?_l=fo</Citation></Reference><Reference><Citation>Tiecco G, Storti S, Degli Antoni M, Foc&#xe0; E, Castelli F, Quiros-Roldan E. Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review. Int J Mol Sci. 2022;23:1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8876558</ArticleId><ArticleId IdType="pubmed">35216104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. Lancet. 2022;399:437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>